1. Home
  2. Services
  3. Cancer Care
  4. Programs
  5. Current Clinical Trials

Current Cancer Clinical Trials
at DeKalb Medical

Emory Decatur Hospital is currently participating in a number of cancer clinical trials. If you see an open trial below that you're interested in, please contact your physician. For additional trials that may be available to Emory Decatur Hospital patients, please visit the Georgia Center for Oncology Research & Education (CORE) website.

Our program is affiliated with many study bases, including the National Cancer Institute co-operative group studies. Emory Decatur Hospital recently joined the Georgia Cares minority-based NCORP (NCI Community Oncology Research Program) based at Georgia Regents University Cancer Center. The Georgia Cares NCORP brings state-of-the-art clinical trials sponsored by the National Cancer Institute will be provided to our patients close to home. If you need further assistance, email us at clinicaltrials@dekalbmedical.org or call us at 404.501.EASY.

ALLIANCE  A011106

This study is designed for women who are post-menopausal and have estrogen and progesterone receptor positive breast cancer with a tumor greater than or equal to at least 2 cm. The purpose of this study is to determine if one hormone blocking agent or a combination of two hormone blocking agents is superior in shrinking the breast cancer prior to surgery.

ALLIANCE  A011202

This study will evaluate whether radiation therapy is as effective as lymph node dissection. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells.

ALLIANCE  A011401

This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed.

ALLIANCE  A011502

This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

NSABP  B-51

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.

NSABP  B-55 

This study is designed for women who have  a breast cancer that is “triple-negative” and known to have the BRCA1 or BRCA2 mutation.  The study will determine if adding a drug known as a PARP inhibitor, after chemotherapy, will improve outcomes and longer disease free survival for these patients.

NRG BR-003 

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer.

ECOG EA1131 

This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Normal Tissue Collection for Comparison to Breast Cancer Tissue.

AGENDIA FLEX

This study is designed for all patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEXRegistry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.

SWOG S1207

This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.

SWOG S1416 

This randomized phase II trial studies how well cisplatin works with or without veliparib in treating patients with stage IV triple-negative breast cancer and/or breast cancer (BRCA) mutation-associated breast cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

SWOG S1418

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

GOG 0225

This randomized phase III trial studies whether changes in diet and physical activity can increase the length of survival without the return of cancer (progression-free survival) compared with usual care in patients with previously treated stage II, III, or IV ovarian, fallopian tube, or primary peritoneal cancer. A healthy diet and physical activity program and counseling may help patients make healthier lifestyle choices.

GOG 0286B

This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

ALCHEMIST A151216

The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial represents three integrated, precision medicine trials that are designed to identify people with early-stage lung cancer who have tumors that harbor EGFR and ALK gene alterations and evaluate whether drug treatments targeted against those molecular changes can lead to improved survival compared to current standard of care therapy alone.

The three components are:
  • ALCHEMIST -- Screening Component (A151216)
  • ALCHEMIST -- EGFR Treatment component (A081105)
  • ALCHEMIST – ALK Treatment component (E4512)

ALCHEMIST A081105

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient?s tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

ALCHEMIST EA5142

This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.

SWOG S1400

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid "Master Protocol" (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting.

EA6134

This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery. Ipilimumab and nivolumab may block tumor growth by targeting certain cells. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene.

contact us

FIND A DOCTOR online bill pay access my account

Emory Decatur Hospital Cancer Center
2675 North Decatur Rd.
Suite 103
Decatur, GA 30033

Contact Us Online

    404.501.SCHD (7243)

Mobile Directions
in the News
Visit Press Releases